An observational study in Coronary Heart Disease, sponsored by Centre Hospitalier Régional Metz-Thionville. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-06.
Sponsored by Centre Hospitalier Régional Metz-Thionville · Observational
This work suggests a methodology to adapt the injected radionuclide activity to the level of attenuation of each patient. The investigators propose a dose reduction adapted to the patient's weight, with no significant degradation of the image quality, in order to improve patients and staff radioprotection, standardize the image quality for easier clinical interpretation, and lead to radiopharmaceutical saving in the context of myocardial perfusion Imaging.
3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.
This study's enrollment of 294 is close to the median of 294 across 1,241 observational studies indexed under Heart Diseases.
Browse Heart Diseases studies →Centre Hospitalier Régional Metz-Thionville is the lead sponsor of 118 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient with myocardial perfusion Imaging in the context of coronary heart disease
Exclusion Criteria:
Number of counts
Number of counts in the myocardial region of interest
Time frame: Day 1
Clinical evaluation
Medical evaluation of image quality, in order to establish a correlation between the myocardial signal level and the clinical image quality
Time frame: Day 1
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Régional Metz-Thionville